Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(145 products)
- Bcr-Abl(102 products)
- EGFR(572 products)
- FAK(72 products)
- FLT(92 products)
- Fibroblast Growth Factor Receptor (FGFR)(170 products)
- JAK(245 products)
- PDGFR(126 products)
- RAAS(86 products)
- Src(78 products)
- Syk(38 products)
- Thrombin(47 products)
- VDA(2 products)
- VEGFR(268 products)
Show 6 more subcategories
Found 1414 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
EGFR-IN-31
CAS:<p>EGFR-IN-31: Potent EGFR inhibitor, targets mutations & overexpression in NSCLC; potential cancer research compound. (WO2021185298A1, 2)</p>Formula:C32H36FN7O2Color and Shape:SolidMolecular weight:569.67FLT3/D835Y-IN-1
CAS:<p>FLT3/D835Y-IN-1, an oral FLT3 inhibitor (IC50: FLT3 - 0.26 nM, D835Y - 0.18 nM), shows anticancer potential in AML research.</p>Formula:C22H21N5O3Color and Shape:SolidMolecular weight:403.43EGFR-IN-60
CAS:<p>EGFR-IN-60: oral anticancer drug, inhibits EGFR/JAK3, effective on H1975/A431 cells, promotes apoptosis.</p>Formula:C28H28Cl2N6OColor and Shape:SolidMolecular weight:535.47ZT55
CAS:<p>ZT55: Oral JAK2 inhibitor, IC50: 0.031 μM, hinders JAK2 V617F HEL cell growth, induces apoptosis, arrests cell cycle, effective in mice HEL tumor studies.</p>Formula:C17H16N2O3Color and Shape:SolidMolecular weight:296.32VEGFR-2-IN-24
CAS:<p>VEGFR-2-IN-24 is a potent inhibitor of VEGFR-2 (IC50: 0.22 μM) and can be used to study tumors.</p>Formula:C28H23N3O6SColor and Shape:SolidMolecular weight:529.56FGFR4-IN-11
CAS:<p>FGFR4-IN-11: selective, covalent FGFR4 inhibitor; IC50=2.1 nM; blocks FGF19 pathway; anticancer.</p>Formula:C29H29N5O5Color and Shape:SolidMolecular weight:527.57c-Met-IN-14
CAS:<p>c-Met-IN-14: selective c-Met kinase inhibitor, IC50 2.89 nM, anticancer, stops G2/M phase, induces A549 cell apoptosis.</p>Formula:C34H38ClFN4O7SColor and Shape:SolidMolecular weight:701.2EGFR-IN-26
CAS:<p>EGFR-IN-26 is an EGFR inhibitor that can be used in cancer research.</p>Formula:C29H34N6O3Color and Shape:SolidMolecular weight:514.62TRK/ALK-IN-1
<p>TRK/ALK-IN-1: Potent dual TRK & ALK inhibitor; IC50s: 2.2nM (TRKA), 9.3nM (ALK WT), 38nM (ALK L1196M); cancer research potential.</p>Formula:C31H35ClF2N8O2SColor and Shape:SolidMolecular weight:657.18FGFR3-IN-1
CAS:<p>FGFR3-IN-1 (compound 1) is a fibroblast growth factor receptor (FGFR) inhibitor that inhibits FGFR1 (IC50: 40 nM), FGFR2 (IC50: 5.1 nM) and FGFR3 (IC50: 12 nM).</p>Formula:C28H39N9O3SColor and Shape:SolidMolecular weight:581.73EGFR-IN-49
CAS:<p>EGFR-IN-49 selectively inhibits EGFR mutations T790M (IC50: 65 nM) & T790M/L858R (IC50: 13.6 nM), triggering apoptosis dose-dependently.</p>Formula:C22H15N5O2SColor and Shape:SolidMolecular weight:413.45TIE-2/VEGFR-2 kinase-IN-1
CAS:<p>TIE-2/VEGFR-2 kinase-IN-1 synthesizes inhibitors for angiogenesis-related disease research.</p>Formula:C13H11N3O2Color and Shape:SolidMolecular weight:241.25Erbstatin
CAS:<p>Erbstatin is a tyrosine-protein kinase inhibitor. When combined with foroxymithine, it has antineoplastic activity against L-1210 leukemia.</p>Formula:C9H9NO3Color and Shape:SolidMolecular weight:179.17PD-173956
CAS:<p>PD-173956 is an inhibitor of the Src family tyrosine kinases.</p>Formula:C20H13Cl2FN4OColor and Shape:SolidMolecular weight:415.25EGFR-IN-55
CAS:<p>"EGFR-IN-55 targets EGFRWT (70 nM IC50) & EGFRL858R/T790M (3.9 nM IC50), halts NCI-H1975 cell cycle in G0/G1, showing anticancer properties."</p>Formula:C25H25Cl2N7O2Color and Shape:SolidMolecular weight:526.42CP-690550A
CAS:<p>Cp-690550a is a novel JAK3 inhibitor, which is used to treat rheumatoid arthritis, graft rejection, psoriasis, and other immune-mediated diseases.</p>Formula:C15H21N5O2Color and Shape:SolidMolecular weight:303.36Nazartinib mesylate
CAS:<p>Nazartinib mesylate is a novel, covalent mutant-selective inhibitor of EGFR (Ki and Kinact: 31 nM and 0.222/min on EGFR(L858R/790M) mutant).</p>Formula:C27H35ClN6O5SPurity:98%Color and Shape:SolidMolecular weight:591.12MDK5466
CAS:<p>MDK5466 is an Flt3 inhibitor that acts by preventing glutamate-induced cell death.</p>Formula:C21H23N3OSPurity:98%Color and Shape:SolidMolecular weight:365.49HIV-IN-6
CAS:<p>HIV-IN-6, an anti-HIV agent, blocks replication by targeting SFKs like Hck involved with Nef protein.</p>Formula:C20H16N4O3SPurity:97.12%Color and Shape:SolidMolecular weight:392.43Lavendustin C6
CAS:<p>Lavendustin C6 is a effective tyrosine kinase inhibitor.</p>Formula:C20H25NO5Color and Shape:SolidMolecular weight:359.42TRK II-IN-1
CAS:<p>TRK II-IN-1: potent type II TRK inhibitor; IC50s: TRKA (3.3 nM), TRKB (6.4 nM), TRKC (4.3 nM), TRKA G667C (9.4 nM); also targets FLT3, RET, VEGFR2.</p>Formula:C29H31F3N8OPurity:98%Color and Shape:SolidMolecular weight:564.6EGFR-IN-88
CAS:<p>EGFR-IN-88 (Compound 4i), an EGFR inhibitor with an IC50 of 87 nM, exhibits cytotoxic effects on A549 cells at an IC50 of 3.902 μM and can induce cell apoptosis</p>Formula:C22H18Cl2N4O2SPurity:98%Color and Shape:SolidMolecular weight:473.37BAY 2476568
CAS:<p>BAY 2476568 is a selective and potent EGFR inhibitor that acts on both wild-type EGFR (IC50 <0.2 nM) and mutant EGFR (IC50 <0.2 nM).</p>Formula:C24H27FN4O4Color and Shape:SolidMolecular weight:454.49FGFR4-IN-5
CAS:<p>FGFR4-IN-5: potent, selective FGFR4 inhibitor, IC50 6.5 nM, strong in vivo anti-tumor effect, for liver cancer research.</p>Formula:C23H23Cl2N5O5Color and Shape:SolidMolecular weight:520.37DPPY
CAS:<p>DPPY inhibits EGFR, BTK, JAK3 (IC50<10 nM), curbs B-cell lymphoma growth, and may be studied for IPF treatment.</p>Formula:C25H26ClN7O3Color and Shape:SolidMolecular weight:507.97PDGFRα/FLT3-ITD-IN-1
CAS:<p>PDGFRα/FLT3-ITD-IN-1 are potent inhibitors of PDGFRα/FLT3, and their IC50 values are greater than 0.036 and 0.003 μM, respectively.</p>Formula:C27H39N9OColor and Shape:SolidMolecular weight:505.66KRC-108
CAS:<p>KRC-108 is a potent kinase inhibitor targeting Ron, Flt3, TrkA, and c-Met with strong anti-proliferative effects on various cancer cells.</p>Formula:C20H20N6OColor and Shape:SolidMolecular weight:360.41YF-452
CAS:<p>YF-452 inhibits tumor growth through antiangiogenesis by suppressing VEGF receptor 2 signaling.</p>Formula:C24H26BrN3OPurity:98%Color and Shape:SolidMolecular weight:452.39Multi-kinase-IN-3
CAS:<p>Multi-kinase-IN-3 (compound 2) is a potent inhibitor of angiokinase and inhibits VEGFR-2 (IC50: 58.3 nM) and PDGFRβ (IC50: 55 nM).</p>Formula:C33H33N5O3Color and Shape:SolidMolecular weight:547.65VEGFR-2-IN-30
<p>VEGFR-2-IN-30: VEGFR-2 inhibitor, IC50 66 nM; blocks PDGFR, EGFR & FGFR1; halts cancer cell cycle, induces apoptosis.</p>Formula:C28H23ClN6O4S2Color and Shape:SolidMolecular weight:607.1VEGFR-2-IN-21
CAS:<p>VEGFR-2-IN-21 is a potent inhibitor of VEGFR-2 (IC50: 0.10 μM) and exhibits anticancer effects.</p>Formula:C28H24ClN7O3SColor and Shape:SolidMolecular weight:574.05VEGFR-2-IN-22
CAS:<p>VEGFR-2-IN-22 blocks VEGFR-2/beta-tubulin, IC50=19.82 nM, induces apoptosis.</p>Formula:C26H24ClFN4O6Color and Shape:SolidMolecular weight:542.94SYK/JAK-IN-1
CAS:<p>SYK/JAK-IN-1 is a dual SYK/JAK inhibitor with IC50 values of less than 5 nM for both SYK and JAK2.</p>Formula:C24H26N8O3Color and Shape:SolidMolecular weight:474.52FGFR-IN-7
CAS:<p>FGFR-IN-7: Oral FGFR modulator, crosses blood-brain barrier, neuroprotective, phospholipidosis-resistant, useful for neurodegeneration study.</p>Formula:C16H21ClF2N4O2Color and Shape:SolidMolecular weight:374.81EMI56
CAS:<p>EMI56, a derivative of EMI1, exhibits enhanced potency against mutant EGFR compared to EMI1. Additionally, EMI56 effectively inhibits EGFR triple mutants[1].</p>Formula:C21H20N2O3Color and Shape:SolidMolecular weight:348.4EGFR-IN-39
CAS:<p>EGFR-IN-39, an acrylamide, is a potent EGFR inhibitor and antitumor agent targeting NSCLC with low toxicity. See WO2021185348A1 for details.</p>Formula:C24H25ClN6O3Color and Shape:SolidMolecular weight:480.95EMI48
CAS:<p>EMI48, a derivative of EMI1, exhibits increased efficacy against mutant EGFR compared to EMI1. It specifically inhibits EGFR triple mutants [1].</p>Formula:C21H20N2O3Color and Shape:SolidMolecular weight:348.4Lck Inhibitor III
CAS:<p>Lck Inhibitor III, a potent inhibitor of Lck, exhibits an IC50 value of 867 nM.</p>Formula:C25H30N6O4Color and Shape:SolidMolecular weight:478.54K 00546
CAS:<p>K00546 inhibits CDK1/cyclin B (IC50: 0.6 nM), CDK2/cyclin A (IC50: 0.5 nM), CLK1 (IC50: 8.9 nM), and CLK3 (IC50: 29.2 nM).</p>Formula:C15H13F2N7O2S2Purity:99.12%Color and Shape:SolidMolecular weight:425.44EGFR/BRAFV600E-IN-1
CAS:<p>EGFR/BRAFV600E-IN-1 inhibits EGFR (0.08 μM) & BRAFV600E (0.15 μM), affects A-549, MCF-7, Panc-1 & HT-29 (IC50: 0.79-1.3 μM).</p>Formula:C24H24ClN3O3Color and Shape:SolidMolecular weight:437.92PF-00956980
CAS:<p>PF-00956980: reversible JAK inhibitor, IC50: JAK1 (2.2μM), JAK2 (23.1μM), JAK3 (59.9μM), for lung/skin inflammation research.</p>Formula:C18H26N6OColor and Shape:SolidMolecular weight:342.44Debio 0617B
CAS:<p>Debio 0617B inhibits kinases for AML stem cell treatment, targeting JAK, ABL, SRC, and STAT3-related tumours.</p>Formula:C28H23ClF3N7O2Color and Shape:SolidMolecular weight:581.98FAK/aurora kinase-IN-1
CAS:<p>FAK/aurora kinase-IN-1, a dual inhibitor of FAK and aurora kinase, has IC50 values of 6.61 nM and 0.91 nM respectively, and demonstrates anticancer effects (WO2018019252A1; compound 11) [1].</p>Formula:C23H24ClN7O3Color and Shape:SolidMolecular weight:481.93GW694590A
CAS:<p>GW694590A (UNC10112731) functions as a MYC protein stabilizer that enhances the levels of endogenous MYC protein. It also acts on receptor tyrosine kinases, inhibiting DDR2, KIT, and PDGFRα by 81%, 68%, and 67% at a concentration of 1 μM, respectively. As a protein kinase inhibitor, GW694590A affects both ATP-dependent and ATP-independent luciferases, potentially influencing the Fluc reporter gene [1].</p>Formula:C22H19N5O4Color and Shape:SolidMolecular weight:417.42EGFR mutant-IN-2
CAS:<p>EGFR mutant-IN-2 (Compound D51) is an inhibitor of EGFR mutants, specifically targeting EGFR L858R/T790M/C797S and EGFR del19/T790M/C797S mutants with IC50 values of 14 nM and 62 nM, respectively. This compound exhibits favorable pharmacokinetic (PK) parameters, safety properties, in vivo stability, and demonstrates antitumor activity [1].</p>Formula:C27H27F3N6O2SColor and Shape:SolidMolecular weight:556.6Rac-ZINC4085554
CAS:<p>Compound 1T-0219 (SC) is a blocker of AKT1-FAK interaction reducing the stimulation of FAK phosphorylation in response to extracellular pressure in human SW620</p>Formula:C20H19N3O7Purity:90%Color and Shape:SolidMolecular weight:413.38VI 16832
CAS:<p>VI 16832 is a broad-spectrum Type I kinase inhibitor used to quantify relative kinase abundance and study signaling across SILAC-encoded cancer cell lines.</p>Formula:C22H25N5O2Purity:98%Color and Shape:SolidMolecular weight:391.47EGFR-IN-2
CAS:<p>EGFR-IN-2 is a oral and mutation-selective EGFR inhibito,NSCLC, with high selectivity for resistant single and double mutant T790M.</p>Formula:C26H33N9O3SPurity:98.52% - 99.79%Color and Shape:SolidMolecular weight:551.66Nimotuzumab
CAS:<p>Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).</p>Purity:95.00% - 98.5% (SDS-PAGE); 96.4% (SEC-HPLC)Color and Shape:LiquidENMD-1198
CAS:<p>ENMD-119 is a 2-methoxyestradiol analog with antiproliferative and antiangiogenic activity. It is suitable for inhibiting HIF-1α and STAT3 in human HCC cells.</p>Formula:C20H25NO2Purity:98%Color and Shape:SolidMolecular weight:311.42
